1. HBW Insight
  2. >>Geography
  3. >>North America

Nail Care Likely To Face Scrutiny Under California Reg

 
• By Suzanne Blecher

With the release of the first formal draft of California’s Safer Consumer Products Regulation, firms need to begin taking inventory of their raw materials, identifying substances that could be deemed “chemicals of concern” and working with suppliers and other companies to gather human safety and environmental data, according to PCPC Associate General Counsel Tom Myers.

The Personal Care Products Council says cosmetics firms – and nail-care companies in particular – should start anticipating regulatory changes under California’s Safer Consumer Products Regulation, released in its first formal draft July 27.

In an Aug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 
• By Eileen Francis

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

Adcomm Reform: Getting Needed Information More Important Than Vote Or Discussion

 
• By Derrick Gingery

US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

 
• By Malcolm Spicer

Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.